Table 2 Baseline characteristics of the patients in training and validation cohorts according to LA
Characteristic | Training cohort | Validation cohort | ||||
|---|---|---|---|---|---|---|
LA (≤ 80.17) | LA (> 80.17) | P value | LA (≤ 80.17) | LA (> 80.17) | P value | |
(n = 249) | (n = 207) | (n = 115) | (n = 117) | |||
Gender (male/female) | 169/80 | 158/49 | 0.046 | 82/33 | 97/20 | 0.035 |
Age (≤ 55/ > 55,years) | 189/60 | 163/44 | 0.472 | 85/30 | 103/14 | 0.006 |
Smoke (no/yes) | 155/94 | 123/84 | 0.538 | 69/46 | 61/56 | 0.228 |
Drink (no/yes) | 224/25 | 191/16 | 0.390 | 101/14 | 101/16 | 0.733 |
WHO pathological type (I/II/III) | 0/18/231 | 0/14/193 | 1.000 | 1/6/108 | 2/8/107 | 0.837 |
EBV DNA (negative/positive) | 125/124 | 86/121 | 0.065 | 59/56 | 44/73 | 0.036 |
T stage (T1-T2/T3-T4) | 93/156 | 86/121 | 0.361 | 46/69 | 58/59 | 0.143 |
N stage (N0-N1/N2-N3) | 111/138 | 91/116 | 0.895 | 49/66 | 56/61 | 0.421 |
TNM stage (I-II/III-IVa) | 46/203 | 49/158 | 0.174 | 20/95 | 32/85 | 0.069 |